Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tharimmune Advances TH104 for Fentanyl Defense After FDA Positive Feedback
Details : TH104 is a buccal film formulation, of nalmefene specifically designed for rapid absorption with a potential for bypassing liver metabolism.
Product Name : TH104
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2025
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : USAMRICD
Deal Size : Undisclosed
Deal Type : Agreement
SMSbiotech Begins Research Partnership with U.S. Army on Chemical Defense
Details : Under theagreement, SMSbiotech and USAMRICD will conduct joint research focused on evaluating the efficacy of SMS cells in mitigating sulfur mustard-induced pulmonary morbidities.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 22, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : USAMRICD
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Zentiva
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : Under the terms of collaboration, Zentiva will complement their product offering with the support of longstanding partners Adalvo with new molecules in a variety of therapeutical areas like Respiratory, CNS and Dermatology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Zentiva
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : $32.0 million
Deal Type : Financing
Details : Third Pole's technology generates pure inhaled nitric oxide (iNO) for therapeutic use and delivers it to the patient on demand, providing clinicians with greater flexibility than with iNO therapeutics stored in compressed gas cylinders.
Product Name : eNOfit
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 14, 2022
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : $32.0 million
Deal Type : Financing
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Beyond Air to Participate in Three Upcoming Medical Conferences
Details : Nitric Oxide (NO) is a powerful molecule, naturally synthesized in human body, proven to play a critical role in a broad array of biological functions. In airways, NO targets vascular smooth muscle cells that surround small resistance arteries in lungs.
Product Name : LungFit PRO
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 18, 2022
Lead Product(s) : Nitric Oxide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Aptar Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Aptar Pharma Acquires Worldwide License for Orbital™ High Payload Dry Powder Inhaler
Details : Pharmaxis’ proprietary Orbital™ inhaler, a unique device designed to deliver high payload dry powder to the lungs.This unique platform was originally developed as a life cycle extending product for the Pharmaxis cystic fibrosis drug Bronchitol® (man...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 08, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Aptar Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : HCmed Innovations
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration sets forth the framework by which both companies will work together to develop a new nebulized LABA/LAMA combination formulation for the treatment of chronic obstructive pulmonary disease (COPD).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 10, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : HCmed Innovations
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Richard King Mellon Foundation
Deal Size : $0.2 million
Deal Type : Funding
Details : The funding will support pivotal/Phase III cellular therapy study that uses an intravenous injection of autologous stromal vascular fraction (SVF) cells, derived at point-of-care using the GID BIO SVF-2 technology platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 18, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Richard King Mellon Foundation
Deal Size : $0.2 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Citius Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Novellus, a Cambridge, Mass-based cell engineering company, has developed patented, non-immunogenic mRNA-based induced mesenchymal stem cell (iMSC) platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 10, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Citius Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S. Food and Drug Administration (FDA) in regards to its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) to treat and reduce the severity of acute respiratory distress syndrome (ARDS) in patients with COVID...
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 26, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable